After anal cancer treatment: late effects and surveillance
Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
Most people treated for anal cancer are cured. What follows is a long tail of changes that are rarely discussed in advance and are frequently treatable once named.
Surveillance here is unusually hands-on, because recurrence is found by examining the area rather than by a blood test.
Related pages: Anal cancer
The bottom line
- Surveillance is by examination and anoscopy, every 3 to 6 months for several years.
- Pelvic radiation causes bowel, sexual and bone late effects in a substantial proportion of people.
- Vaginal narrowing after pelvic radiation is common and dilator use reduces it.
- Most local recurrences are detected within the first 2 to 3 years.
- How best to treat radiation-related bowel urgency, where options are limited and evidence is thin.
- How long surveillance should continue, which varies between guidelines.
The story, step by step
What the evidence labels mean
What follow-up involves
What happens
The schedule, and why it looks like this.
What the research shows
- Follow-up is clinical: a digital rectal examination, examination of the groin nodes, and anoscopy, typically every 3 to 6 months for the first 2 to 3 years and less often thereafter, usually to 5 years.
- Imaging is used selectively rather than routinely, often for people who had node-positive or advanced disease.
- There is no blood marker for anal cancer, which is why the examination cannot be skipped.
- Most recurrences happen in the first 2 to 3 years and are found by examination, which is the reason the schedule is front-loaded.
- Appointments involving repeated examination of an area that has been through this treatment are difficult for many people. Saying so is reasonable and the team can often make it more tolerable.
- Report new bleeding, pain, a lump, or a change in bowel habit between appointments rather than waiting for the next one.
Why it matters
The intensity of follow-up reflects that salvage surgery works best when recurrence is found early.
What's still uncertain
- The optimal duration and frequency of surveillance, which differs between guidelines.
Read more
- National Cancer Institute: Anal cancer treatment (PDQ)Government
- National Cancer Institute: Survivorship and late effectsGovernment
- MedlinePlus: Anal cancerGovernment
Next: Bowels
What changes, and what helps
What happens
The most common long-term effect.
What the research shows
- Increased frequency, urgency, incomplete emptying and clustering of bowel movements are common afterwards and may persist.
- Some degree of leakage or urgency incontinence affects a meaningful minority. It is underreported because people assume it is the price of cure.
- Pelvic floor physiotherapy helps, and is the first thing to ask for. It is underused in this group.
- Bulking agents, loperamide taken proactively rather than reactively, bile acid sequestrants where bile acid malabsorption is present, and dietary adjustment all have a role.
- Radiation proctitis can cause bleeding months to years later and is treatable, including with argon plasma coagulation where needed.
- Bile acid malabsorption and small intestinal bacterial overgrowth after pelvic radiation are both recognized, both testable and both treatable, and both are frequently missed.
- Anything that is limiting your life is worth raising. The default assumption that nothing can be done about post-radiation bowel function is wrong.
Why it matters
A specialist late-effects or pelvic radiation disease service exists in some centres and is the right referral where available.
What's still uncertain
- How effective each intervention is for radiation-related bowel dysfunction, where trials are few.
Read more
- National Cancer Institute: Survivorship and late effectsGovernment
- National Cancer Institute: Anal cancer treatment (PDQ)Government
- MedlinePlus: Anal cancerGovernment
Next: Sex and hormones
The part that gets least airtime
What happens
Common, treatable, and rarely raised.
What the research shows
- For women, pelvic radiation causes vaginal dryness, shortening and narrowing. Regular dilator use, usually started a few weeks after treatment once healing allows, keeps the vagina usable for examination and for sex. Moisturizers and lubricants are part of this.
- Pelvic radiation almost always causes premature menopause in premenopausal women. Hormone therapy is often appropriate and should be discussed rather than assumed to be off-limits.
- For men, erectile dysfunction is common after pelvic radiation, and testosterone can fall. Both are treatable.
- Pain with sex after this treatment is common and is a physiotherapy and medical issue, not something to push through.
- Nobody is likely to raise this unless you do. Surveys consistently find sexual late effects are the least discussed and among the most distressing.
- Intimacy without penetration, and open conversation with a partner, carry people through the period when the rest is not possible.
Why it matters
Dilators and vaginal moisturizers are standard care, not an optional extra, and starting late makes the outcome worse.
What's still uncertain
- How much early dilator use prevents stenosis, which is accepted practice on modest evidence.
Read more
- National Cancer Institute: Sexual health issues in people with cancerGovernment
- National Cancer Institute: Survivorship and late effectsGovernment
- National Cancer Institute: Anal cancer treatment (PDQ)Government
Next: Other late effects
Bone, lymph and skin
What happens
The rest of the list.
What the research shows
- Pelvic insufficiency fractures, particularly of the sacrum, occur after pelvic radiation and present as lower back or buttock pain. They are often mistaken for recurrence and are managed conservatively.
- Bone density falls after pelvic radiation and after premature menopause. Vitamin D, calcium and a DEXA scan are reasonable to ask about.
- Lymphoedema of the legs or genitals can follow treatment of the groin nodes, and responds to specialist lymphoedema therapy.
- Skin in the treated area stays thinner, darker and more fragile, and is more sun-sensitive permanently.
- Second cancers related to HPV, including cervical, vulvar and oropharyngeal, are more likely in this group, so other screening stays relevant.
- Fatigue often takes 6 to 12 months to resolve, and exercise is the best-evidenced treatment for it.
Why it matters
Several of these are mistaken for recurrence, which is its own kind of distress. Knowing they exist makes the first episode less frightening.
What's still uncertain
- The true incidence of insufficiency fractures, which is probably underestimated because many are not imaged.
Read more
- National Cancer Institute: Survivorship and late effectsGovernment
- National Cancer Institute: Anal cancer treatment (PDQ)Government
- MedlinePlus: Radiation therapyGovernment
Next: The rest of it
Stigma, work and survivorship
What happens
The non-medical part.
What the research shows
- Anal cancer carries stigma that other cancers do not, partly because of the HPV link and partly because people find the site itself embarrassing to discuss.
- People report concealing the diagnosis, calling it bowel or colorectal cancer, and losing the support that usually comes with a cancer diagnosis as a result.
- Nobody gives themselves anal cancer. HPV is close to universal, most people clear it, and persistent infection is largely a matter of immune luck. That is worth saying plainly.
- Anal cancer peer support groups exist and are reported as unusually valuable here, precisely because the subject is hard to raise elsewhere.
- Ask for a written survivorship care plan: the treatment received, the doses, what is monitored and for how long, and which late effects to watch for.
- Returning to work often needs adjustment for bowel urgency and toilet access, which is a reasonable accommodation to request.
- Fear of recurrence peaks around follow-up appointments and is treatable. Psycho-oncology services exist for this.
Why it matters
The social difficulty of this cancer is a real clinical problem, not a sensitivity, and it affects whether people seek help for the rest.
What's still uncertain
- How much stigma contributes to delayed presentation and poorer follow-up, which is documented but not quantified.